BDSX
BIODESIX INC
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$21.49
+2.09%Oct 22, 2026, 10:00 UTC
Biodesix announced that it will release its third-quarter 2026 financial results after market close on November 5, 2026, and hold a conference call and webcast at 4:30 p.m. Eastern Time that day.
Source:Oct 19, 2026, 10:00 UTC
BIODESIX INC announced a partnership with Vanderbilt University and Vanderbilt University Medical Center to accelerate development of a radiomics-based test for lung nodule risk assessment.
Source:Sep 24, 2026, 10:00 UTC
Biodesix announced two complementary approaches to molecular residual disease (MRD) monitoring, a tumor-informed program and a tumor-naïve program, drawing on its bioinformatics and diagnostics test development expertise.
Source:Aug 5, 2026, 20:01 UTC
Biodesix reported second quarter 2026 revenue of $26.9 million, a 34% increase year over year, with an 82% gross margin, and maintained its full-year 2026 revenue guidance of $108-114 million.